News
Looking for a biopharma job in Pennsylvania? Check out the BioSpace list of nine companies hiring life sciences professionals like you.
FEATURED STORIES
PitchBookâs 2025 biopharma VC analysis clocked $33.8 billion in capital dispatched in 2025, mainly to companies with later-stage programs ready to roll into the clinic.
Long an R&D company that partnered off assets, RNAi biotech Ionis Pharmaceuticals shifted in 2025 to bring two medicines to market alone. Analysts are already impressedâand thereâs more to come in 2026.
Regulatory uncertainty is no longer background noise. It is a material investment risk that reshapes how capital is deployed and pipelines are prioritized.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
The FDAâs refusal to review Modernaâs mRNA-based flu vaccine is part of a larger communications crisis unfolding at the agency over the past nine months that has also ensnarled Sarepta, Capricor, uniQure and many more.
THE LATEST
BMO analysts say Eli Lilly is well-positioned to maintain its lead in the ballooning weight loss space, predicting âstrengthening leadership in obesity and beyondâ as portfolios expand and patient access improves.
Biopharma companiesâincluding AstraZeneca, BioNTech and Agiosâpeered farther into the future on the second day of JPM, setting both revenue and R&D targets through the end of the decade.
AstraZeneca is relying on several upcoming products to help hit its target of $80 billion in revenue by 2030, including drugs for hypertension, breast cancer and generalized myasthenia gravis, all of which are currently under FDA review.
A more detailed review of data by the FDA showed that GLP-1 drugs do not increase the risk of suicidal ideation or behavior.
AbbVie and Novartis strike billion-dollar pacts while attendees at the J.P. Morgan Healthcare Conference await that one big M&A deal and Merck teases limitless buying capacity; Eli Lilly readies for potential orforglipron launch while Novo Nordisk laments compounders; the IPO window cracks open; and the FDA concludes that GLP-1s do not pose a suicide risk.
Speaking to BioSpace at the J.P. Morgan Healthcare Conference, Novartisâ chief dealmaker Ronny Gal explains why the Swiss pharma hasnât acquired a GLP-1, and why it probably wonât.
There hasnât been a headline-stealing deal at J.P. Morgan yet. Nevertheless, the mood is positive amid green shoots and a flurry of dealmaking to end 2025.
Merck CEO Rob Davis expressed high confidence during the companyâs J.P. Morgan presentation on Monday, revealing that the company is open to deals in the range of âmulti tens of billions of dollars.â
Acadia Pharmaâs Catherine Owen Adams is one of the founders of a group of small- to mid-cap biotechs advocating against a âpeanut butter blanketâ approach to drug pricing for small companies.
Johnson & Johnsonâs second facility in Wilson, North Carolina, is part of a $55 billion push to make all advanced medicines used in the U.S. domestically.